依达拉奉联合巴曲酶治疗进展性脑梗死的疗效评价

Assess effects of edaravone combined with batroxobin in treatment of progressive cerebral infarction patients

目的观察依达拉奉联合巴曲酶治疗进展性脑梗死的疗效。方法选择发病在48h内进展性脑梗死患者80例,随机分为治疗组(40例)和对照组(40例),两组均用巴曲酶治疗,治疗组加用依达拉奉,观察治疗后神经功能改善情况及血浆纤维蛋白原(Fb)含量的变化。结果3周后治疗组有效率85%,高于对照组72.5%(P<0.05),两次治疗后Fb水平较治疗前明显降低(均P<0.01)。结论依达拉奉联合巴曲酶治疗进展性脑梗死安全有效。

Objective To observe the efficacy of edaravone combined with batroxobin for progressive cerebral infarction. Methods The study was performed on progressive cerebral infarction patients （ 80cases）, enrolled within 48 hour of onset. They were randomly divided into treatment group（40patients） and control group （40patients）. Thc treatment group was allocated edaravone and batroxobin, and control group was allocated batroxobin. And then to observe the improvement of neurological function and the change of the fibrinogen in the blood. Results After three weeks, the apparent rate of the treatment group was 85%, higher than that of the control group 72.5% （P 〈 0.05 ）. After two treatments the fibrinogen cut down dramatically（ both P 〈 0.01 ）. Conclusion Edaravone combined with batroxobin is an effective and safe therapy method for treating progressive cerebral infarction.